Executives On The Move: New CEOs Named At Melinta Therapeutics And PIC Therapeutics
Swedish Orphan Biovitrum names R&D head while Regulus Therapeutics gets a new chief scientific officer and Zealand Pharma a new head of investor relations.
You may also be interested in...
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
Diffusion Pharmaceuticals and WPD Pharmaceuticals get new chief medical officers.